Crossref
Belimumab: Where Are We Three Years After FDA Approval?
Current Treatment Options in Rheumatology · 2015
DOI: 10.1007/s40674-014-0001-4 ↗Kurz gefasst
Fachartikel in der Zeitschrift Current Treatment Options in Rheumatology, 2015. Verfasst von Daniel J. Wallace. Die Arbeit nennt 33 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
Wallace, D. J. (2015). Belimumab: Where Are We Three Years After FDA Approval?. Current Treatment Options in Rheumatology. https://doi.org/10.1007/s40674-014-0001-4
Vancouver
Wallace DJ. Belimumab: Where Are We Three Years After FDA Approval?. Current Treatment Options in Rheumatology. 2015. doi:10.1007/s40674-014-0001-4
BibTeX
@article{Wallace2015,
author = {Wallace, Daniel J.},
title = {Belimumab: Where Are We Three Years After FDA Approval?},
journal = {Current Treatment Options in Rheumatology},
year = {2015},
doi = {10.1007/s40674-014-0001-4}
}
EUVIMED